First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

@article{Vogel2001FirstLineHM,
  title={First-Line Herceptin® Monotherapy in Metastatic Breast Cancer},
  author={C. Vogel and M. Cobleigh and D. Tripathy and J. Gutheil and L. N. Harris and L. Fehrenbacher and D. Slamon and M. Murphy and W. Novotny and M. Burchmore and S. Shak and S. Stewart},
  journal={Oncology},
  year={2001},
  volume={61},
  pages={37 - 42}
}
  • C. Vogel, M. Cobleigh, +9 authors S. Stewart
  • Published 2001
  • Medicine
  • Oncology
  • The pivotal phase II and III Herceptin® trials proved the efficacy and safety of second- or third-line single-agent Herceptin and first-line Herceptin in combination with chemotherapy, respectively. In the current trial, 114 patients were randomized to one of two dose groups of first-line Herceptin monotherapy: standard dose of 4 mg/ kg initial dose followed by 2 mg/kg intravenous (i.v.) weekly; or high dose of 8 mg/kg initial dose followed by 4 mg/kg i.v. weekly. The regimen was generally well… CONTINUE READING
    201 Citations

    Figures, Tables, and Topics from this paper

    Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
    • T. Repka, E. Chiorean, +4 authors J. Miller
    • Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 2003
    • 92
    • PDF
    An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
    • 100
    Trastuzumab-containing regimens for metastatic breast cancer.
    • 139
    • PDF
    Trastuzumab containing regimens for early breast cancer.
    • 437

    References

    SHOWING 1-10 OF 23 REFERENCES
    Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
    • M. Pegram, A. Lipton, +8 authors D. Slamon
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1998
    • 1,051
    Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
    • M. Cobleigh, C. Vogel, +8 authors D. Slamon
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1999
    • 2,722
    Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
    • J. Baselga, D. Tripathy, +11 authors L. Norton
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 1,375
    Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    • 9,112
    • PDF
    Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
    • 683
    • PDF